Opinion

Video

Choosing Between Oral JAK Inhibitors in Atopic Dermatitis

Ruth Ann Vleugels, MD, MPH, MBA, provides insights on factors that inform JAK inhibitor treatment selection for patients with atopic dermatitis.

Video content above is prompted by the following questions:

  • How do you choose between different JAK inhibitors? What role do efficacy and safety data play in your selection?
  • What are important considerations when choosing a JAK inhibitor in specific patient populations (e.g., older adults ≥65 yr)?
Related Videos
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
Discussing 140-Week Data on Upadacitinib for Atopic Dermatitis, with Raj Chovatiya, MD, PhD
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis
New ‘Level Up’ Data on Upadacitinib (Rinvoq) for Atopic Dermatitis, with Christopher Bunick, MD, PhD
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
© 2024 MJH Life Sciences

All rights reserved.